Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,670 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05916261RecruitingEarly Phase 1
Personalized pancreatic cancer vaccines with pembrolizumab
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
Qionghai, HainanAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07229625RecruitingPhase 3
New drug combination for advanced bile duct cancer
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
Hangzhou, ZhejiangAges 18–75 - NCT06708858RecruitingPhase 2
Studying surufatinib with chemo and immunotherapy for advanced bile duct cancer
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07537348RecruitingPhase 2
Leucine-restricted diet with chemotherapy for advanced stomach cancer
This study tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy can safely treat advanced stomach cancer that has spread. Researchers want to see if this dietary approach helps the treatment work better and reduces side effects.
Jinan, ShandongAges 18–70 - NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT06234397RecruitingPhase 1
Study of BH3120 with or without pembrolizumab for advanced cancers
This trial tests a new drug, BH3120, alone or with pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the combination can help your immune system fight cancer more effectively.
Tampa, FloridaAges 18 years+ - NCT06715501Enrolling by invitation
Testing cadonilimab with chemo and radiation for advanced esophageal cancer
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
Ningbo, ZhejiangAges 18–75 - NCT07180082RecruitingPhase 2
Pyrotinib for HER2-positive advanced breast cancer
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
ShanghaiAges 18 years+ - NCT06494514Recruiting
New chemo combo with immunotherapy and radiation for advanced pancreatic cancer
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
Nanjing, JiangsuAges 18 years+ - NCT07527858RecruitingPhase 2
Study of Denikitug with immunotherapy or chemotherapy for advanced colorectal cancer
This trial tests a new drug called denikitug, given alone or combined with other cancer treatments, for patients with advanced colorectal cancer that hasn't responded to previous treatments. The goal is to help people whose cancer has a specific genetic profile (MSS) that doesn't respond well to standard immunotherapy alone.
North Haven, ConnecticutAges 18 years+ - NCT05681650RecruitingPhase 1/Phase 2
HER2-targeted CAR-T for HER2-positive advanced solid tumors
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07484724RecruitingPhase 2
JS212 combination therapy for advanced esophageal cancer
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07469774RecruitingPhase 1/Phase 2
BC3195 plus Keytruda for advanced solid tumors
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT05653453RecruitingPhase 3
Tumor treatment device plus chemo for locally advanced pancreatic cancer
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Harbin, HeilongjiangAges 18–75 - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06092580RecruitingPhase 1
Study of AWT020 for advanced solid tumors and lymphoma
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
South Brisbane, QueenslandAges 18 years+ - NCT05831878Recruiting
Drug RC48 for HER2-low or HER2-ultralow breast cancer
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
ShanghaiAges 18 years+ - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06404281RecruitingPhase 1
Modified immune cells for advanced solid tumors
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
ChangzhouAges 18–80 - NCT06974812RecruitingPhase 1/Phase 2
Study of IBI3014 for advanced solid tumors
This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT04891016RecruitingPhase 2
Immunotherapy with chemotherapy for locally advanced stomach cancer
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Zhengzhou, HenanAges 18–70 - NCT07591090RecruitingPhase 2
Drug combination study for advanced HER2-negative breast cancer
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06111274RecruitingPhase 2
ABSK021 for untreated advanced pancreatic cancer
This trial tests a new drug called ABSK021 for people with advanced pancreatic cancer who have not received any prior treatment. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,670 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.